The Yellow Card Scheme

The MHRA and the Commission on Human Medicines (CHM) run the UK's spontaneous adverse drug reaction (ADR) reporting scheme - called the Yellow Card Scheme. This receives reports of suspected adverse drug reactions (ADRs) or side effects from healthcare professionals and patients for medicines and vaccines.

The Yellow Card Scheme is the main ADR reporting scheme in the UK and was introduced in 1964 after the thalidomide tragedy highlighted the urgent need for routine monitoring of medicines. It receives about 25,000 reports of possible side effects each year.


Information for patients

Doctor with female patient
This section contains information about the Yellow Card scheme for patients
The unwanted display of the text is removed here...dont delete this

Information in other languages

International flags
Yellow Card scheme information is available in other languages
The unwanted display of the text is removed here...dont delete this

Case studies

Doctor with a young woman
This page provides case studies about the impact of the Yellow Card scheme and how it helps patients and healthcare professionals.
The unwanted display of the text is removed here...dont delete this

History of the Yellow Card scheme

Yellow card on a laptop
This page provides information about the history of the Yellow Card scheme and how it has evolved since its conception over 40 years ago
The unwanted display of the text is removed here...dont delete this

Information for healthcare professionals

Doctor reading his laptop
This section provides information on healthcare professionals on adverse drug reactions, including what to report, how to report and answers to frequently asked questions.

Using Yellow Card data to protect public health

Hand filling out form
Information on how public health is protected through the collection of Yellow Card reports

Yellow Card data

Computers showing data
Information on Yellow Card data

Information for the pharmaceutical industry

Mother and child with pharmacist
This section provides information for pharmaceutical companies on the reporting of suspected adverse drug reaction (ADR) reports
Page last modified: 20 May 2013